Literature DB >> 24343119

Tight versus standard blood pressure control in patients with hypertension with and without cardiovascular disease.

Gianpaolo Reboldi1, Fabio Angeli, Giovanni de Simone, Jan A Staessen, Paolo Verdecchia.   

Abstract

An excessive blood pressure (BP) reduction might be dangerous in high-risk patients with cardiovascular disease. In the Studio Italiano Sugli Effetti CARDIOvascolari del Controllo della Pressione Arteriosa SIStolica (Cardio-Sis), 1111 nondiabetic patients with systolic BP ≥150 mm Hg were randomly assigned to a systolic BP target <140 mm Hg (standard control) or <130 mm Hg (tight control). We stratified patients by absence (n=895) or presence (n=216) of established cardiovascular disease at entry. Antihypertensive treatment was open-label and tailored to each patient's needs. After 2-year follow-up, the primary end point of the study, electrocardiographic left ventricular hypertrophy, occurred less frequently in the tight than in the standard control group in the patients without (10.8% versus 15.2%) and with (14.1% versus 23.5%) established cardiovascular disease (P for interaction=0.82). The main secondary end point, a composite of cardiovascular events and all-cause death, occurred less frequently in the tight than in the standard control group both in patients without (1.47 versus 3.68 patient-years; P=0.016) and with (7.87 versus 11.22 patient-years; P=0.049) previous cardiovascular disease. In a multivariable Cox model, allocation to tight BP control reduced the risk of cardiovascular events to a similar extent in patients with or without overt cardiovascular disease at randomization (P for interaction=0.43). In conclusion, an intensive treatment aimed to lower systolic BP<130 mm Hg reduced left ventricular hypertrophy and improved clinical outcomes to a similar extent in patients with hypertension and without established cardiovascular disease.

Entities:  

Keywords:  hypertension; hypertrophy, left ventricular; myocardial infarction; prognosis; randomized controlled trial; stroke

Mesh:

Substances:

Year:  2013        PMID: 24343119     DOI: 10.1161/HYPERTENSIONAHA.113.02089

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  9 in total

Review 1.  Primary prevention: do the very elderly require a different approach?

Authors:  Janice B Schwartz
Journal:  Trends Cardiovasc Med       Date:  2014-10-18       Impact factor: 6.677

2.  Pulse pressure is not an independent predictor of outcome in type 2 diabetes patients with chronic kidney disease and anemia--the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT).

Authors:  S Theilade; B Claggett; T W Hansen; H Skali; E F Lewis; S D Solomon; H-H Parving; M Pfeffer; J J McMurray; P Rossing
Journal:  J Hum Hypertens       Date:  2015-03-26       Impact factor: 3.012

Review 3.  Blood pressure targets for the treatment of people with hypertension and cardiovascular disease.

Authors:  Luis Carlos Saiz; Javier Gorricho; Javier Garjón; Mª Concepción Celaya; Juan Erviti; Leire Leache
Journal:  Cochrane Database Syst Rev       Date:  2018-07-20

4.  Blood pressure targets for the treatment of people with hypertension and cardiovascular disease.

Authors:  Luis Carlos Saiz; Javier Gorricho; Javier Garjón; Mª Concepción Celaya; Juan Erviti; Leire Leache
Journal:  Cochrane Database Syst Rev       Date:  2020-09-09

5.  Prevalence of Hypertension among Patients Attending Mobile Medical Clinics in the Philippines after Typhoon Haiyan.

Authors:  Linda Meta Mobula; Mary Lou Fisher; Nathan Lau; Abi Estelle; Tom Wood; William Plyler
Journal:  PLoS Curr       Date:  2016-12-20

6.  The distribution of cardiac diagnostic testing for acute coronary syndrome in the Brazilian healthcare system: A national geospatial evaluation of health access.

Authors:  Julian T Hertz; Tommy Fu; Joao Ricardo Vissoci; Thiago Augusto Hernandes Rocha; Elias Carvalho; Brendan Flanagan; Luciano de Andrade; Alex T Limkakeng; Catherine A Staton
Journal:  PLoS One       Date:  2019-01-10       Impact factor: 3.240

Review 7.  Preterm Birth and Hypertension: Is There a Link?

Authors:  Mariane Bertagnolli; Thuy Mai Luu; Adam James Lewandowski; Paul Leeson; Anne Monique Nuyt
Journal:  Curr Hypertens Rep       Date:  2016-04       Impact factor: 5.369

8.  Long term outcomes of cluster randomized trial to improve cardiovascular health at population level: The Cardiovascular Health Awareness Program (CHAP).

Authors:  Simone Dahrouge; Janusz Kaczorowski; Lisa Dolovich; Michael Paterson; Lehana Thabane; Karen Tu; Jaime Younger; Larry Chambers
Journal:  PLoS One       Date:  2018-09-06       Impact factor: 3.240

Review 9.  Advances in the Treatment Strategies in Hypertension: Present and Future.

Authors:  Paolo Verdecchia; Claudio Cavallini; Fabio Angeli
Journal:  J Cardiovasc Dev Dis       Date:  2022-03-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.